STOCK TITAN
  1. Home
  2. News
  3. VCNX

Vaccinex, Inc. - VCNX STOCK NEWS

Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.

Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company headquartered in Rochester, NY. Specializing in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines, and other biologic products, Vaccinex is dedicated to addressing serious diseases with unmet medical needs, including cancer, multiple sclerosis, and other autoimmune diseases.

The company is pioneering a unique approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). Vaccinex's leading drug candidate, pepinemab, is designed to block SEMA4D, a potent agent believed to prevent immune infiltration into tumors and reduce inflammation in chronic brain diseases. Currently, pepinemab is undergoing evaluation in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease. Additionally, there is ongoing exploration for potential Phase 3 development in Huntington's disease.

Vaccinex conducts research both in-house and through collaborations with prominent academic institutions and biotechnology firms. The company's proprietary drug discovery platform, ActivMAb, plays a significant role in its innovative drug development approach. The development team at Vaccinex comprises experienced industry veterans skilled in therapeutic biologics research, manufacturing, quality control, toxicology, pharmacology, regulatory affairs, and clinical affairs.

Recently, Vaccinex has achieved notable milestones, including a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards and the advancement of its clinical trials. The company continues to secure funding for its research, with significant investments from the Alzheimer’s Drug Discovery Foundation and grants from the Alzheimer’s Association.

Vaccinex remains committed to advancing its clinical programs and expanding its pipeline of innovative therapies to improve patient outcomes in challenging diseases.

News

Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

Rhea-AI Summary
Vaccinex, Inc. will be presenting novel findings for its lead product, pepinemab, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The studies demonstrate that pepinemab induces the formation of lymphoid structures in tumors, which promote efficient immune responses and improved outcomes to immune checkpoint inhibitors. In the Phase 2 KEYNOTE-B84 study, pepinemab in combination with Merck's anti-PD-1 therapy showed a doubling of objective responses and progression-free survival in patients with hard-to-treat tumors. Another study with collaborators at Emory University showed that pepinemab in combination with nivolumab and/or ipilimumab induced tertiary lymphoid structures in tumors, resulting in ongoing response in 8 out of 8 patients for more than 2 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
clinical trial
-
News

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Rhea-AI Summary
Vaccinex reports positive findings for its lead product, pepinemab, in treating brain inflammation. The drug significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, indicating its potential to reverse harmful astrocyte activation. A randomized, placebo-controlled trial is currently underway to test the drug's effectiveness in Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
none
-
News

Vaccinex Announces Pricing of $9.6 Million Public Offering

Rhea-AI Summary
Vaccinex, Inc. announces securities purchase agreements for the sale of 9.6M shares of common stock and warrants, expected to raise $9.6M in gross proceeds. The funds will be used for the development of its lead drug candidate and other corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.17%
Tags
offering
News

Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration

Rhea-AI Summary
Vaccinex announces a new publication in the journal mAbs describing a novel way in which its proprietary ActivMAb® poxvirus platform can enable the presentation of high complexity, hard-to-drug proteins as targets for antibody discovery. The application was successfully used with OmniAb's platform to select antibodies against challenging multipass membrane targets. This new application is a powerful complement to Vaccinex's ActivMAb platform and can accelerate the development of novel therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.82%
Tags
none
-
News

Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application

Rhea-AI Summary
Vaccinex to present update on Phase 1b/2 pepinemab/PDAC study and new ActivMAb® application
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
conferences
-
News

Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

Rhea-AI Summary
Vaccinex, Inc. will report on novel findings for its lead product, pepinemab, at upcoming medical conferences. Results from the phase 2 SIGNAL trial suggest pepinemab has the potential to prevent decline in brain metabolic activity and slow cognitive decline in Huntington's disease. In combination with a checkpoint inhibitor, pepinemab has shown the potential to induce formation of lymphoid structures in tumors, leading to improved outcomes in head and neck cancer. The company believes pepinemab may be an attractive alternative or combination therapy for Alzheimer's disease. The Phase 2 KEYNOTE-B84 study demonstrated improved objective response rates and progression-free survival in head and neck squamous cell carcinoma patients treated with pepinemab and KEYTRUDA. Treatment with pepinemab in combination with KEYTRUDA also appeared to induce formation of highly organized lymphoid structures in tumors, which correlated with disease control and progression-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.64%
Tags
none
News

Vaccinex, Inc. Announces Reverse Stock Split

Rhea-AI Summary
Vaccinex, Inc. announces a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Vaccinex, Inc. announced financial results for Q2 2023 and provided updates on clinical milestones. The Phase 1b/2 SIGNAL-AD trial of pepinemab in Alzheimer's disease achieved full accrual and is expected to complete 12-months treatment in June 2024. Interim results from the Phase 2 KEYNOTE-B84 trial in head and neck cancer showed promising outcomes. Vaccinex is also initiating clinical studies in metastatic pancreatic cancer and breast cancer. The company's cash and cash equivalents were $1.9 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
earnings
-
News

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
earnings

FAQ

What is Vaccinex, Inc.?

Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies, vaccines, and biologic products to treat serious diseases, including cancer and autoimmune diseases.

Where is Vaccinex, Inc. located?

Vaccinex, Inc. is based in Rochester, NY.

What is Vaccinex's lead drug candidate?

Vaccinex's lead drug candidate is pepinemab, which targets semaphorin 4D (SEMA4D) and is being studied for its potential to treat cancer and neurodegenerative diseases.

What is the focus of Vaccinex's research?

Vaccinex focuses on treating serious diseases with unmet medical needs, such as cancer, multiple sclerosis, and other autoimmune diseases.

What clinical studies is pepinemab involved in?

Pepinemab is currently being evaluated in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease.

What is the ActivMAb platform?

ActivMAb is Vaccinex's proprietary drug discovery platform that aids in the development of its innovative therapeutic products.

Who are Vaccinex's research partners?

Vaccinex collaborates with world-class academic institutions and biotechnology companies for its discovery research.

What recent milestone has Vaccinex achieved?

Vaccinex recently completed a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards.

How is Vaccinex funded?

Vaccinex has received significant investments and grants, including funding from the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association.

Who leads the development team at Vaccinex?

Vaccinex's development team is led by experienced industry veterans with expertise in various fields such as therapeutic biologics research, manufacturing, and regulatory affairs.

Stock VCNX logo
Vaccinex, Inc.

Nasdaq:VCNX

VCNX Rankings

#5437 Ranked by Market Cap
N/A Ranked by Dividends

VCNX Stock Data

10.68M
1.58M
6.81%
50.42%
1.27%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
ROCHESTER